Our Insights Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More Chronic Disease Anthony Iannacci 3/20/24 Chronic Disease Anthony Iannacci 3/20/24 Xolair for food allergies: effective therapy at a high price Read More Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More Oncology Anthony Iannacci 10/3/22 Oncology Anthony Iannacci 10/3/22 CAR-T Outlook Read More Chronic Disease Anthony Iannacci 7/26/22 Chronic Disease Anthony Iannacci 7/26/22 Prospects for ulotaront in schizophrenia Read More Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More Oncology Anthony Iannacci 5/12/22 Oncology Anthony Iannacci 5/12/22 Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC Read More Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More Oncology Anthony Iannacci 11/4/21 Oncology Anthony Iannacci 11/4/21 Prioritizing Indications: An Analytical Framework Read More Oncology Anthony Iannacci 5/6/21 Oncology Anthony Iannacci 5/6/21 Trodelvy: A New Option for Later Lines TNBC Read More Oncology Anthony Iannacci 10/16/20 Oncology Anthony Iannacci 10/16/20 Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL Read More Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More Oncology Anthony Iannacci 7/21/20 Oncology Anthony Iannacci 7/21/20 Pfizer Combo Gains an Edge in BRAF+ Melanoma Read More Chronic Disease Anthony Iannacci 7/15/20 Chronic Disease Anthony Iannacci 7/15/20 Trikafta: A Major Step Forward for Cystic Fibrosis Patients Read More Oncology Anthony Iannacci 6/2/20 Oncology Anthony Iannacci 6/2/20 A Reliable Predictor of NICE Recommendation Read More Oncology Anthony Iannacci 5/27/20 Oncology Anthony Iannacci 5/27/20 Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma Read More Oncology Anthony Iannacci 5/4/20 Oncology Anthony Iannacci 5/4/20 Lynparza: Expanding into Prostate Cancer Read More Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More Newer Posts Older Posts
Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More
Chronic Disease Anthony Iannacci 3/20/24 Chronic Disease Anthony Iannacci 3/20/24 Xolair for food allergies: effective therapy at a high price Read More
Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More
Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More
Chronic Disease Anthony Iannacci 7/26/22 Chronic Disease Anthony Iannacci 7/26/22 Prospects for ulotaront in schizophrenia Read More
Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More
Oncology Anthony Iannacci 5/12/22 Oncology Anthony Iannacci 5/12/22 Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC Read More
Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More
Oncology Anthony Iannacci 11/4/21 Oncology Anthony Iannacci 11/4/21 Prioritizing Indications: An Analytical Framework Read More
Oncology Anthony Iannacci 5/6/21 Oncology Anthony Iannacci 5/6/21 Trodelvy: A New Option for Later Lines TNBC Read More
Oncology Anthony Iannacci 10/16/20 Oncology Anthony Iannacci 10/16/20 Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL Read More
Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More
Oncology Anthony Iannacci 7/21/20 Oncology Anthony Iannacci 7/21/20 Pfizer Combo Gains an Edge in BRAF+ Melanoma Read More
Chronic Disease Anthony Iannacci 7/15/20 Chronic Disease Anthony Iannacci 7/15/20 Trikafta: A Major Step Forward for Cystic Fibrosis Patients Read More
Oncology Anthony Iannacci 6/2/20 Oncology Anthony Iannacci 6/2/20 A Reliable Predictor of NICE Recommendation Read More
Oncology Anthony Iannacci 5/27/20 Oncology Anthony Iannacci 5/27/20 Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma Read More
Oncology Anthony Iannacci 5/4/20 Oncology Anthony Iannacci 5/4/20 Lynparza: Expanding into Prostate Cancer Read More
Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More
Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More
